Summit Tx Capital, L.P. Cytokinetics Inc Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
A detailed history of Summit Tx Capital, L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 13,357 shares of CYTK stock, worth $398,572. This represents 0.02% of its overall portfolio holdings.
Number of Shares
13,357Holding current value
$398,572% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
404Shares Held
126MCall Options Held
3.7MPut Options Held
890K-
Black Rock Inc. New York, NY14.7MShares$438 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$354 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$297 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$238 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$182 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $2.81B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...